Integrated DNA Technologies, Inc.
Coralville, IA Doing business as I D T Part of Beckman Coulter, Inc.
- UEI
- P55FTN1UMYZ1
- CAGE
- 1V0C1
- Primary NAICS
- 325199 All Other Basic Organic Chemical Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Danaher Corporation, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Beckman Coulter, Inc. · Brea, CA
Z4DRFM3LMJB8
-
- UMW2GFAMB8E3
- K88ZYBC4U726
-
-
Parent
Beckman Coulter, Inc. · Brea, CA
Z4DRFM3LMJB8
- SAM.gov registration date
- Physical address
- 1710 Commercial Park, Coralville, IA 52241, USA
- Website
- idtdna.com
- Founded
- 1987
- Employees
- 1K-5K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $328,239 |
| FY2025 | $280,504 |
| FY2024 | -$1,287,106 |
| FY2023 | $1,372,731 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $125,553 | |
| 2 | Department of Health and Human Services | $101,117 | |
| 3 | Department of the Navy | $93,500 | |
| 4 | Department of the Interior | $8,069 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| IDT DNA synthesis service | Food and Drug Administration | $24,000 | |
| Integrated DNA technologies INC:1107504 [26-009060] | Office of Logisitics and Acquisition Operations (NIH) | $77,117 | |
| Oligonucleotide cards | Office of Naval Research (SECNAV) | $93,500 | |
| Reagents | Defense Health Agency | $102,994 | |
| PA-lamar FHC-custom DNA oligonucleotides | Fish and Wildlife Service | $8,069 |
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| The Johns Hopkins University | HHSN268201700006I | $49,883 | |
| Mriglobal | N6600121C4048 | $62,767 | |
| Mriglobal | N6600121C4048 | $35,510 | |
| Mriglobal | N6600121C4048 | $231,858 |
Latest 4 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| LGC Biosearch Technologies | Petaluma, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Twist Bioscience Corporation | South San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eurofins Genomics LLC | Louisville, KY | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Biolytic Lab Performance Inc. | Fremont, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Edge Biosystems Inc. | San Jose, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Integrated DNA Technologies, Inc., doing business as IDT, is a manufacturer of custom DNA and RNA oligonucleotides, primers, probes, gene fragments, and specialized molecular biology reagents that serves as a prime contractor to 49 distinct federal agencies, competing without set-aside designation in full-and-open procurement. IDT is a subsidiary of Beckman Coulter, Inc., headquartered in Coralville, Iowa, and operates under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) and PSC 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets), with a federal award footprint spanning 691 total awards across the past two decades.
The vendor's customer concentration is heavily skewed toward pandemic response and public health agencies. The Centers for Disease Control and Prevention Pittsburgh accounts for 34 awards and $282 million in combined potential value—92% of IDT's total federal pipeline—driven primarily by task orders for SARS-CoV-2 sequencing reagents, spike primer sets, and custom oligonucleotides issued under two recurring Blanket Purchase Agreements with the National Institutes of Health (HHSN263200400060954B and HHSN263201500214B), which together carry 32 task orders valued at $392 thousand. The Defense Health Agency ranks second with 10 awards worth $6.4 million across both a newly awarded $5 million single-award BPA (effective September 17, 2024 through September 16, 2029) and prior task orders for custom reagents and supplies supporting the Walter Reed Army Institute of Research. The National Institutes of Health agencies collectively represent significant volume: the National Human Genome Research Institute (25 awards, $353 thousand), the National Institute of Allergy and Infectious Diseases (17 awards, $218 thousand), the National Heart Lung and Blood Institute (12 awards, $377 thousand), the National Institute of Neurological Disorders and Stroke (which holds a $10 million BPA established September 5, 2024 through September 30, 2027), and the National Center for Advancing Translational Sciences (11 awards, $1.1 million) drive ongoing demand for oligonucleotides, gene synthesis, antisense oligonucleotides for neurotoxicity and viral research, and sequencing reagents.
IDT holds two active prime indefinite delivery vehicles with federal agencies: the $5 million Defense Health Agency BPA (September 2024–September 2029) and the $10 million National Institute of Neurological Disorders and Stroke BPA (September 2024–September 2027), both supporting custom oligonucleotide synthesis and specialized molecular biology products. A third major vehicle, the $2.5 million Department of Veterans Affairs Federal Supply Schedule contract for in vitro diagnostics, reagents, test kits, and custom DNA/RNA synthesis (awarded May 31, 2022), appears in the source as ultimately expiring July 31, 2018 on paper but remains cited across numerous awards through at least mid-2024, suggesting contract renewal or renewal pending. Representative prime-contract work includes a $627,939.66 definitive contract from the Defense Health Agency (June 24, 2024) for reagents and consumables supporting the Walter Reed Army Institute of Research (completion August 13, 2028); a $701,584 order from the National Center for Advancing Translational Sciences (July 14, 2022) for synthesis of 13,492 antisense oligonucleotides supporting a SARS-CoV-2 study; a $670,359.20 purchase order from CDC Pittsburgh (March 10, 2022) for custom reagents for SARS-CoV-2 genomic sequencing; and a $187,940 sole-source purchase order from CDC Pittsburgh (September 12, 2024) for spike primer sets and amplicon panels using IDT's proprietary xGen technology, the only validated platform for whole genome sequencing of SARS-CoV-2.
Activity has remained flat year over year across 2022–2024 (18–20 awards per year) before declining to 11 awards in 2025 and 6 awards in 2026 year to date, reflecting wind-down of pandemic-era procurement intensity. Three awards carrying $729 thousand in combined potential value are slated for completion within the next twenty-four months, presenting a recompete exposure concentrated in the CDC's prior-year SARS-CoV-2 reagent orders. The vast majority of IDT's federal footprint is prime work (685 awards, 99%); subcontract engagement is minimal, limited to five named orders under MRIGlobal for the Programmable Platform-Agnostic Nucleic Acid Detection Assays (PANDA) program and one order for 96-well adapter plates under an unspecified prime. The vendor's top NAICS classifications reflect its core product lines: All Other Basic Organic Chemical Manufacturing (141 awards), In-Vitro Diagnostic Substance Manufacturing (47 awards), and Biological Product Manufacturing (21 awards). The award portfolio heavily skews toward laboratory equipment and supplies (260 awards) and drugs and biologicals (100 awards) across PSC codes, cementing IDT's position as a specialized molecular reagent supplier rather than a broad-based life-sciences contractor.
Quick answers
Is Integrated DNA Technologies, Inc. registered in SAM.gov?
Yes. Integrated DNA Technologies, Inc.'s SAM.gov registration is active through April 13, 2027.
How much has Integrated DNA Technologies, Inc. received in federal contracts?
Federal contracts obligated $280,504 to Integrated DNA Technologies, Inc. in fiscal year 2025 and $694,369 in fiscal years 2023 through 2027.
How does Integrated DNA Technologies, Inc. rank among federal contractors?
Integrated DNA Technologies, Inc.'s parent company, Danaher Corporation, ranked #1 in PSC 6550, #1 in NAICS 325413 and #7 in PSC 6640 in FY2025.
What is Integrated DNA Technologies, Inc.'s most recent federal award?
Integrated DNA Technologies, Inc.'s most recent federal contract award is IDT DNA synthesis service (75F40126P00288), from Food and Drug Administration, on September 15, 2026.
On GovTribe
See Integrated DNA Technologies, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors